Much appreciated Cousin, thanks very much for the report. |
 If the other chap that was there doesn't report back, I can.
Steadfastly nothing financial nor commercial was said that hasn't been announced already.
Appreciate that there may be confirmation bias here, but the laser focus on delivering the 3 year targets was evident and the understated confidence of doing this also.
Impression given that cost savings are complete and employee morale is good with appreciation of wider market (biotech winter) and that OXB can grow significantly from here with the current strategy. This includes the newer sites and the cross transferring of wider capabilities to each. Any recruitment is also attracting high calibre candidates.
Given the 'on script' performance in anything remotely market sensitive, questions around the long term did provoke responses about being THE best, go to provider in the CGT CDMO space. Technology agnostic but aiming to keep advancing through internal R&D and, by implication, M&A were an exceptional opportunity to present itself. That was about the most passionate Frank became, although there were a few nice touches of humour during the meeting. |
ArcticZymes Technologies Announces Nomination of Dr. Frank Mathias as Chairman of the Board
Tue, Jun 25, 2024 08:26 CET Report this content
Tromsø, Norway – June 25, 2024 – ArcticZymes Technologies (OSE:AZT) is pleased to announce the nomination of Dr. Frank Mathias as the new Chairman of the Board.
Dr. Mathias is the CEO at Oxford Biomedica, a leading pure-play CDMO within the cell and gene therapy industry. Dr. Mathias was previously the CEO of Rentschler Biopharma SE, which he successfully developed into a leading global, full-service CDMO. Prior to Rentschler, Dr. Mathias served as CEO of Medigene AG, a publicly listed immuno-oncology company. During his 30-year career, Dr. Mathias has held senior roles at leading global pharmaceutical companies, including Amgen Deutschland GmbH, Servier Deutschland GmbH, and Hoechst AG. In 2019, he was awarded the “EY Entrepreneur of the Year” title in Germany. Dr. Mathias is a pharmacist by training and completed his Doctorate in Pharmacy at Paris VI University.
“We are very pleased to nominate Frank Mathias as our new Chairman of the Board,” said Jon R. Sandberg, Chairman of the Nomination Committee. “Frank Mathias’ extensive experience and visionary leadership make him the ideal candidate to guide our company into its next phase of development, commercialization and growth.”
“I am honoured to join ArcticZymes at such a pivotal time,” said Dr. Frank Mathias. “The innovative enzyme solutions developed by ArcticZymes have made significant contributions to advancements in biomanufacturing, enhancing efficiency and quality across the industry. I look forward to contributing to the company’s continued success and collaborative growth.”
About us
ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world. We provide our customers with cold-adapted enzymes from the arctic environment with unique features including heat lability and activity in challenging environments, as well as, customised engineered novel features which can be easily integrated to fuel their innovations. |
It might be urban myth, but I'm sure I remember a court case many years ago where the manager had signed up a new but promising pop group with a 50/50 contract where he would take care of everything.
They went on to do really quite well and he did take care of everything, but the small print was that he got 50% of gross, whilst they were on 50% of what was left and after one European tour it was 50% of nothing.
I'd bet another pound of Dom's money that Mike Tyson's deal with Don King was written in the same ink.
The contributors here who have been to previous AGMs said that young Mr Grace turns up every year. Hope he's still going after the madness of the covid years. |
H, don’t forget our 20yr longstanding lottery 50/50 agreement. I’m sure any great secrets would’ve been shared by now. |
Disappointing GH, but tempered by the fact that I'm winning £180m on the Euromillions tonight ;)
I doubt any great secrets were revealed. |
Last minute event meant I couldn’t attend today. Feedback from any one who made it? |
"just looking for patterns Phil (out of boredom really) "That reminds me of a tale relating to WC Fields.He's sitting in his dressing room,when a friend enters the room,to find the comedian reading the bible."Hey Bill,i didn't know you were a religious man?"........."I'm not",replied Fields,"i'm looking for loopholes,just looking for loopholes". |
I'm just looking for patterns Phil (out of boredom really) but it seems reasonable to me that if they gave us some pretty good updates as the year turned, that they will do similar again at the half year - then of course the actual half year results in detail at the interims in September.
But they might not.
You've seen my posts for years, so you know my glass is half full, but I'm pretty convinced (in fact just convinced) that the story which got ever better in the first few releases of this year is far from finished.
You know my reasons (listed here many times) but I'm hoping that Frank or whoever presented today was very "reassuring" for those who attended. Hopefully we will find out soon... |
As you say Harry, it makes more sense to give metrics for H1, so either this Friday or sometime next week. |
Nothing tagged on to the vote results |
If there is a business update Dom, then I would have expected it either first thing this morning or tagged on to the RNS with the result of the AGM votes later.
As for what they say informally this afternoon, well hopefully we will get to hear what that was by first-hand account a bit later.
I think we all realise that of the things which we actually "know" then the multiple myeloma news from 20th March is probably the biggest.
A little bit more about that would be very welcome. |
3:00pm start. Doesn't suggest they are making time for a business update? |
The Company intends to hold its AGM on Monday 24 June 2024 at the offices of Oxford Biomedica, Windrush Court, Transport Way, Oxford OX4 6LT, commencing at 3:00 p.m. |
Is the agm today? |
Daily drop! Happens every day. |
If you follow this link from a conference last year (Abstracts from The International Society for Aerosols in Medicine: 24th ISAM Congress Saarbrücken, Germany August 26–30, 2023).
Then do CTRL + F and type 3720931 then enter. BI 3720931 is the name of the drug.
(quote)
H. Inhaled Biotherapeutics
H. 01 Lentiviral Vector Based Gene Therapy for Respiratory Diseases
Eric WFW Alton,1,2 A Christopher Boyd,1,3 Jane C Davies,1,2 Deborah Gill,1,4 Uta Griesenbach,1,2 Stephen Hyde,1,4 and Gerry McLachlan1,5
1UK Respiratory Gene Therapy Consortium, London, United Kingdom.
2National Heart and Lung Institute, Imperial College, London, United Kingdom.
3Edinburgh, Edinburgh, United Kingdom.
4Oxford, Oxford, United Kingdom.
5Roslin, Edinburgh, United Kingdom.
Inefficient pulmonary gene transfer is a major factor that has limited the development of a clinically suitable gene therapy for cystic fibrosis (CF). While Sendai virus‐mediated gene transfer to airway epithelial cells is highly efficient, the short duration of expression and strong immunogenicity have rendered Sendai virus‐based vectors ineffective for CF gene therapy.
We have developed a lentiviral vector pseudotyped with the Sendai virus F and HN envelope proteins (rSIV.F/HN), to deliver a normal copy of the CFTR cDNA into the genomic DNA of airway epithelial cells of patients with CF.
With this vector, we have demonstrated efficient and lifelong transduction in the airways of multiple species. In addition it shows the ability to redose, efficiently transduces all of the major airway epithelial cell types and demonstrates restoration of CFTR function in intestinal organoids.
A mutation‐agnostic gene therapy for CF may benefit patients who are genetically ineligible for CFTR modulator therapy, as well as eligible patients who experience adverse reactions or suboptimal responses to this therapy.
The above data support the progression of BI 3720931 towards the clinic, with a first‐in‐;human trial in final preparation for regulatory submission.
(unquote)
But just to repeat, time dragging on like this is very normal in the "first do no harm" world. |
Mirabeau,
It's one of the many things I keep a weather eye out for (the CF trial which hopes to treat the first trial patients with an inhalable version of OXB's LentiVector this summer). As of yet I've seen nothing to suggest a trial recruiting, but would stress that means nothing bad. In non-covid pandemic times regulators are ultra cautious and it's normal for timescales to slip.
My previous post (7430) below:-
Someone a while ago asked about our Cystic Fibrosis research partnership with Boehringer Ingelheim which seemed very quiet.
Interesting link today
Relevant part :-
"After tackling challenges ranging from finding a suitable vector (it's much harder to get genes into the lungs than originally anticipated) to scaling up, the team partnered with Boehringer Ingelheim and Oxford Biomedica in 2018, and is set to begin human trials this summer."
So some good news at long last from that - not just for us, but hopefully a chance of a fix for those with CF too. |
In light of #WearYellowDay for Cystic Fibrosis, we are proud to highlight the great work being done in partnership with Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC, consisting of researchers from Imperial College London, University of Oxford and The University of Edinburgh) and Oxford Biomedica on the development of BI 3720931, a novel, self-inactivating, replication deficient, 3rd generation lentiviral vector, in an inhaled formulation as a potential long-lasting therapeutic option.
There is currently no cure for Cystic Fibrosis – a genetic condition affecting around 11,000 people in the UK that slowly destroys the lungs and digestive system – however the research being done by Boehringer Ingelheim and GTC is a step in the right direction and doing great work in alleviating the symptoms of patients.
To read more about this research, please click here: |
They won’t be turning me away at the door Dom 😂 |
That description belonged to me at previous AGM. I stopped going when Covid restrictions made it on line. In the John Dawson era we small shareholders were at least made to feel welcome and the ability to talk to board members and to listen to a presentation of business was worth going to. The recent regime has not been at all open to shareholders and I do not feel that we are welcome, in fact I am not even sure we would be let in if our shares (as is normal) are held by a nominee of a trading platform. |
I'm sure we'd all appreciate the feedback if there is anything interesting discussed GH. |
My son writes the trading algorithms for his trading desk…it’s an imperfect science with limitations-his words |
Morning Jasie,
If you want my sweeping statement of the day, based upon little more than once having read memoirs like "Liar's Poker" and "FIASCO", then even back in the 1980s the American Banks employed the smartest people in the world (3 post graduate maths degrees I seem to remember in one case) and paid them a fortune to come up with advanced machine trading strategies that mortals couldn't understand.
It worked fantastically well until it didn't, but that's why the books were written.
What I would say is that the algorithmic trades, which are a large part of daily volume on most major exchanges these days, already are machine AI trading with next to no human input - apart from safety breaks to stop trading if it ends up in a death loop.
So I think from the market point of view (ultimate free market of the exchanges) then they are ahead of all this and have been for years - as the incentive was there for them to spend and develop the system.
In every day mainstream life, I think where it affects us more (and at least this is my hope) will be that we should be doing less trials which come to nothing because the AI will have thinned those out at an earlier stage.
There is also the possibility here that AI is simply the next big thing and will have its moment of great hype/hope, before becoming "normal" in a lesser way - like the dot.com boom leaving us with the internet which we have today. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
